3rd Apr 2012 15:00
Director/PDMR Share Dealings
April 3, 2012 - Shire plc , the global specialty biopharmaceutical company (the "Company") announces that it was notified on April 2, 2012 that on March 30, 2012 the Ordinary Shares ("Shares") and American Depository Shares ("ADSs") in the Company set out below had been awarded under the Shire Executive Annual Incentive Plan ("EAIP") to Persons Discharging Managerial Responsibility ("PDMRs"). The Shares and ADSs were acquired on March 30, 2012, at prices of £21.11 per Share and $97.3685 per ADS, respectively.
Type of No of Security Shares/ADSs purchased Angus Russell (Chief Executive Officer) ADSs 2,907 Graham Hetherington (Chief Financial Shares 4,552Officer) Michael Cola ADSs 1,205 Barbara Deptula ADSs 846 Sylvie Gregoire ADSs 1,410 Tatjana May Shares 2,660 Kevin Rakin ADSs 442
The awards will not normally be released to participants for three years. One ADS is equal to three Shares.
In addition, the Company was notified on April 2, 2012 of the release, on the same day, of the following Shares and ADSs awarded in 2009 under the EAIP.
Type of No of Shares/ No of Shares/ Security ADSs released ADSs sold to satisfy tax liabilities
Angus Russell (Chief Executive Shares 37,814 12,264Officer) Graham Hetherington (Chief Financial Shares 9,007 4,659
Officer) Michael Cola ADSs 6,374 2,447 Barbara Deptula ADSs 4,902 2,029 Sylvie Gregoire ADSs 5,631 2,236 Tatjana May Shares 14,010 7,246
On April 2, 2012 sufficient Shares and ADSs were sold to satisfy tax liabilities as set out above. The Shares were sold at a price of £20.14 per Share and the ADSs were sold at an average price of $97.8240 per ADS.
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.
Tony GuthrieDeputy Company Secretary
For further information please contact:
Investor Relations Eric Rojas [email protected] +1 781 482 0999 Sarah Elton-Farr [email protected] +44 1256 894157 Notes to editorsSHIRE PLC
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: www.shire.com.
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
Press Release www.shire.com
XLONRelated Shares:
Shire